Form 8-K · Current report
TransDigm Group 8-K, filed Sep 14, 2026
- Filed
- CIK
- 0001260221
- Accession no.
- 0001260221-26-000056
Summary
TransDigm Group announced that its wholly-owned subsidiary TransDigm Inc. plans to offer $2.5 billion in aggregate principal amount of senior secured notes in a private placement under Rule 144A and Regulation S, subject to market and other conditions. TransDigm Group intends to use the net proceeds to repurchase all of the Issuer's outstanding 6.75% Senior Secured Notes due 2028 through a concurrent tender offer, and for general corporate purposes.
Key points
- The notes would be guaranteed by TransDigm Group and certain direct and indirect subsidiaries of TransDigm Inc.
- The offering is limited to qualified institutional buyers under Rule 144A and to non-U.S. persons under Regulation S.
- The notes and guarantees have not been and will not be registered under the Securities Act.
- TransDigm Group notes risks including its ability to complete the notes offering and the concurrent tender offer for the 2028 Secured Notes.
Written by an AI model from the filing text. It can be incomplete or wrong; the filing on SEC.gov is the record.
Items reported
- 7.01Regulation FD Disclosure
From the filing
Item 7.01. Regulation FD Disclosure. $2,500 Million Senior Secured Notes Offering On September 14, 2026, TransDigm Group Incorporated (“TransDigm Group”) announced that its wholly-owned subsidiary, TransDigm Inc. (the “Issuer”) is planning, subject to market and other conditions, to offer $2,500 million aggregate principal amount of senior secured notes (the “Notes”) pursuant to a confidential offering memorandum in a private placement under Rule 144A and Regulation S of the Securities Act of 1933, as amended (the “Securities Act”). The Notes will be guaranteed by TransDigm Group and certain of the Issuer’s direct and indirect subsidiaries. …
An excerpt of the text as filed with the SEC, cut for length.
Readster writes AI-generated summaries of public filings for research purposes only. Summaries can be incomplete or wrong — check the original filing on SEC.gov before relying on it. Nothing here is investment, legal or medical advice.